ISIN | LU0432979614 |
---|---|
Valor Number | 10261626 |
Bloomberg Global ID | |
Fund Name | JPM Global Healthcare Fund A acc USD |
Fund Provider |
J.P. Morgan Bank Luxembourg S.A.
6, route de Trèves L-2633, Senningerberg Grand Duchy of Luxembourg |
Fund Provider | J.P. Morgan Bank Luxembourg S.A. |
Representative in Switzerland |
JPMorgan Asset Management (Switzerland) LLC Genève Phone: +41 22 744 11 11 |
Distributor(s) |
JP Morgan Asset Management (Europe) Sàrl Senningerberg Phone: +352 34 10 1 |
Asset Class | Equities |
EFC Category | Equity Health Care |
Distribution Policy | Accumulation |
Home Country | Luxembourg |
Issuing Condition | Combination of issuing commission charged by the fund management company and transaction fee charged by the fund |
Redemption Condition | Combination of redemption commission charged by the fund management company and transaction fee charged by the fund |
Investment Strategy *** | To achieve a return by investing primarily in pharmaceutical, biotechnology, healthcare services, medical technology and life sciences companies ("Healthcare Companies"), globally. |
Peculiarities |
Current Price * | 472.74 USD | 02.09.2025 |
---|---|---|
Previous Price * | 471.32 USD | 29.08.2025 |
52 Week High * | 557.48 USD | 03.09.2024 |
52 Week Low * | 437.54 USD | 15.05.2025 |
NAV * | 472.74 USD | 02.09.2025 |
Issue Price * | ||
Redemption Price * | ||
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 3,565,491,166 | |
Unit/Share Assets *** | 913,989,186 | |
Trading Information SIX |
YTD Performance | +1.01% |
31.12.2024 - 02.09.2025
31.12.2024 02.09.2025 |
---|---|---|
YTD Performance (in CHF) | -10.91% |
31.12.2024 - 02.09.2025
31.12.2024 02.09.2025 |
1 month | +4.72% |
04.08.2025 - 02.09.2025
04.08.2025 02.09.2025 |
3 months | +4.54% |
02.06.2025 - 02.09.2025
02.06.2025 02.09.2025 |
6 months | -6.34% |
03.03.2025 - 02.09.2025
03.03.2025 02.09.2025 |
1 year | -15.20% |
03.09.2024 - 02.09.2025
03.09.2024 02.09.2025 |
2 years | +0.36% |
05.09.2023 - 02.09.2025
05.09.2023 02.09.2025 |
3 years | +3.61% |
02.09.2022 - 02.09.2025
02.09.2022 02.09.2025 |
5 years | +10.72% |
02.09.2020 - 02.09.2025
02.09.2020 02.09.2025 |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
Eli Lilly and Co | 7.40% | |
---|---|---|
AbbVie Inc | 7.35% | |
Johnson & Johnson | 7.29% | |
AstraZeneca PLC | 4.85% | |
Boston Scientific Corp | 4.31% | |
Roche Holding AG | 3.96% | |
UnitedHealth Group Inc | 3.96% | |
Stryker Corp | 3.71% | |
Danaher Corp | 3.47% | |
McKesson Corp | 2.82% | |
Last data update | 31.07.2025 |
TER *** | 1.69% |
---|---|
TER date *** | 31.12.2024 |
Performance Fee *** | |
PTR | |
Max. Management Fee *** | 1.50% |
Ongoing Charges *** | 1.69% |
SRRI ***
|
|
SRRI date *** | 31.07.2025 |